Recent KDIGO guidelines [16,17] have highlighted SGLT2 inhibitors as the first therapeutic option for patients with DM2 and chronical kidney disease (CKD), alongside metformin, renin–angiotensin–aldosterone system (RAAS) blockers and statins [18], with the main concern being related to the fact that one in three people with DM also has CKD [19]. Here, SLC5A2 is linked to chronic kidney disease.